Antibodies, an integral part of the immune system, act as formidable defenders against pathogens such as hepatitis C virus (HCV). Monoclonal antibodies (mAb), synthetic analogs produced in laboratories, show remarkable specificity in targeting specific viral components. The main goal of this literature review is to distinguish the exact binding sites of mAbs on the E1 and E2 proteins of the virus.
These proteins control essential viral entry into host cells, making them strategic targets for therapeutic intervention.
By elucidating the molecular interactions between mAbs and E1E2 proteins, researchers are trying to develop therapeutic agents that can effectively prevent viral entry and spread.
Furthermore, this understanding holds promise for the rational design of vaccines aimed at eliciting a strong immune response against HCV. Thus, making these epitopes is a fundamental endeavour with far-reaching implications for therapeutic advances and prevention strategies in the Hepatitis C domain.
Note- There are a lot of Abs and mAbs reported in context of E1E2 as epitopes on HCV. However, for this project, the focus has been primarily on those specific to humans or humanized Abs.
Broadly Neutralizing Antibodies -
Some of the Abs mentioned in the visualization tab are bNAbs. What are they? Broadly neutralizing antibodies (bNAbs) effectively target multiple strains within a virus family, like HIV or HCV. They recognize conserved regions on viral surface proteins, essential for viral entry into host cells. Unlike strain-specific antibodies, bNAbs neutralize diverse variants by binding to stable epitopes. Obtained through prolonged exposure to the virus or engineered immunogens, bNAbs demonstrate high potency and breadth.
They hold promise for therapeutic use in passive immunization and as guides for vaccine design, offering broad protection against viral diseases by targeting shared vulnerabilities across viral strains. Brasher et al. elucidate B cell immunodominance in acute HCV infection, correlating targeting of certain epitopes with plasma neutralization breadth. Understanding these immune responses informs vaccine design strategies to induce potent bNAb responses, crucial for combatting HCV and achieving global elimination targets.